Investigating circulating tumor DNA is a top priority for patients with diffuse large B-cell lymphoma, noted Michael R. Green, PhD, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.
Investigating circulating tumor DNA (ctDNA) for predicting response to chimeric antigen receptor T-cell therapy is a top priority for patients with diffuse large B-cell lymphoma, noted Michael R. Green, PhD, associate professor of lymphoma and myeloma and director, Translational and Laboratory Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.
Transcript
What unanswered questions need to be addressed for patients with diffuse large B-cell lymphoma?
I think there's 3 things that are immediate next steps from the work that we've described in the paper. First of all, I mentioned the association between molecular response and patient outcome. That was in a relatively limited series of patients, in terms of number, so that needs to be validated in a much larger cohort to either validate the existing 3 shots that we've set for predicting response or prospectively determine other informative thresholds moving forward. So, validation of ctDNA for predicting response is number 1.
Number 2: the phenotype that we found to be associated with poor response, and poor molecular response, in particular, was an exhaustion phenotype of CD8 T cells characterized by the co-expression of the LAG-3 [lymphocyte-activation gene 3] and TIM-3 [T-cell immunoglobulin and mucin domain-containing protein 3] co-inhibitory molecules. These are potentially therapeutically targetable, using blocking antibodies that are in early-phase clinical trials. So another immediate next step, which we're pursuing as part of a secret funded study here at MD Anderson, is to see whether LAG-3– and TIM-3–blocking antibodies are able to rescue the function of these exhausted CD8 T cells.
The third would be really validation of not only the association between ICANS [immune effector cell-associated neurotoxicity syndrome] cells and neurotoxicity—we're quite confident about this association, but really, association is not causation—[but] trying to dig in deeper into the causative role that these ICANS-associated cells and monocyte-like cells within the infusion products may have in mechanistically driving neurotoxicity once they're infused into the patient.
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More